Product image of Lamivudine/Zidovudine Viatris (Zidovudine, Lamivudine) supplied by GNH India

Lamivudine/Zidovudine Viatris

Active Ingredient:
Zidovudine, Lamivudine
Origin:
EU

Lamivudine/Zidovudine Viatris (Zidovudine, Lamivudine)

Lamivudine and Zidovudine, the active ingredients in Lamivudine/Zidovudine Viatris, are nucleoside reverse transcriptase inhibitors presented as oral tablets for oral use. They are employed in the treatment of HIV infection and AIDS in adult and pediatric patients. They are administered as part of combination antiretroviral therapy to achieve durable viral suppression.

GNH India supplies Lamivudine/Zidovudine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance for global HIV treatment programs.

Manufacturer / TM Owner

Viatris Gx

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lamivudine/Zidovudine is used as a nucleoside reverse transcriptase inhibitor regimen for HIV‑related conditions.

  • Human immunodeficiency virus (HIV) infection: reduces plasma viral load and delays disease progression.
  • Acquired immunodeficiency syndrome (AIDS): improves immune function and reduces opportunistic infections.
  • Prevention of mother‑to‑child transmission of HIV: lowers the risk of vertical transmission when given to pregnant women.

How It Works

  • Lamivudine and zidovudine are nucleoside analogues that enter cells and undergo phosphorylation to their active triphosphate forms. These active metabolites compete with natural deoxy‑nucleoside triphosphates for incorporation into viral DNA by reverse transcriptase. Incorporation results in chain termination, preventing elongation of the viral genome and thereby inhibiting HIV replication. The combined effect of both agents provides synergistic suppression of viral replication across different stages of the reverse transcription process.

Side Effects

Lamivudine/Zidovudine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea
  • Headache
  • Fatigue
  • Diarrhea
  • Anemia

Serious or Rare Side Effects

  • Lactic acidosis
  • Severe hepatotoxicity
  • Neutropenia
  • Hypersensitivity reactions (including rash and Stevens‑Johnson syndrome)

Precautions & Warnings

Before initiating Lamivudine/Zidovudine, clinicians should consider several safety measures to minimise risk.

  • Baseline and periodic monitoring of complete blood count: detect anemia or neutropenia early.
  • Assess liver function tests before and during therapy: identify hepatotoxicity.
  • Evaluate renal function: dose adjustment may be required in impaired clearance.
  • Avoid use in patients with known hypersensitivity to either component: discontinue if reaction occurs.
  • Use with caution during pregnancy and breastfeeding: weigh benefits against potential risks.
  • Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Lamivudine/Zidovudine can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid)

  • Didanosine: increased risk of pancreatitis and mitochondrial toxicity.
  • Stavudine: heightened mitochondrial toxicity leading to lactic acidosis.
  • Alcohol: may exacerbate hepatotoxic effects.

Moderate Interactions (Monitor Closely)

  • Rifampin: reduces plasma concentrations of both agents, potentially compromising antiviral effect.
  • Nevirapine: may increase risk of liver enzyme elevations.
  • Efavirenz: can affect plasma levels of lamivudine, requiring monitoring.

Frequently Asked Questions

Lamivudine/Zidovudine is an antiretroviral combination indicated for the treatment of HIV infection and AIDS. It is also used to reduce the risk of mother‑to‑child transmission of HIV when administered to pregnant women as part of a complete antiretroviral regimen.

Both lamivudine and zidovudine are nucleoside analogues that, after cellular phosphorylation, become active triphosphates. These active forms compete with natural nucleotides for incorporation into viral DNA by reverse transcriptase, causing premature chain termination and thereby blocking HIV replication.

The dosage of Lamivudine/Zidovudine is individualized by the prescribing clinician based on factors such as patient weight, renal function, and the overall antiretroviral regimen. Patients should follow the exact dosing instructions provided by their healthcare professional.

Limited clinical data are available, but the combination has been used in pregnancy when the benefits outweigh potential risks. Breastfeeding decisions should be made in consultation with a healthcare provider, considering both maternal health and infant exposure.

Enquiries can be submitted through the product page on gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine/Zidovudine offers a well‑established NRTI backbone that is generally less expensive than newer agents such as tenofovir/emtricitabine. While newer drugs may have more convenient dosing or improved safety profiles, the combination remains effective, especially in resource‑limited settings.

The product should be stored at room temperature, below 25 °C, in its original container. Protect it from moisture, direct sunlight and extreme temperatures to maintain stability throughout its shelf life.

Lamivudine/Zidovudine is supplied as oral tablets that are taken with water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber regarding timing relative to meals.

Serious adverse events include lactic acidosis, severe hepatotoxicity, neutropenia and hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if they occur.

Individuals with known hypersensitivity to lamivudine, zidovudine, or any excipients in the tablet should avoid the product. It is also contraindicated in patients with severe bone‑marrow suppression or uncontrolled liver disease without careful medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Zidovudine, Lamivudine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT